Compare Under Armour Inc Class A (UA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs GeneDx Holdings Corp — how do they compare? Under Armour Inc Class A trades at $4.78 (market cap $2.07B), while GeneDx Holdings Corp trades at $67.98 (market cap $2.02B). The key difference: Under Armour Inc Class A and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 2,680,141). Which is the better fit depends on your goals — on Pluang, investors hold Under Armour Inc Class A for 18 Days and GeneDx Holdings Corp for 19 Days on average.
| UA | WGS | |
|---|---|---|
Market Cap | $2.07B | $2.02B |
Volume | 2,680,141 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.88 | $167.51 |
52-Week Low | $3.96 | $34.51 |
Typical Hold Time | 18 Days | 19 Days |
Enterprise Value | $3.05B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
